Infections Caused by Carbapenemase-Producing Klebsiella pneumoniae: Microbiological Characteristics and Risk Factors.


Journal

Microbial drug resistance (Larchmont, N.Y.)
ISSN: 1931-8448
Titre abrégé: Microb Drug Resist
Pays: United States
ID NLM: 9508567

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 28 2 2019
medline: 6 7 2019
entrez: 28 2 2019
Statut: ppublish

Résumé

The spread of carbapenemase-producing Klebsiella pneumoniae (CPKP) worldwide is a serious problem. This retrospective, matched case-control, parallel study in a tertiary teaching hospital analyzed the microbiological and clinical characteristics of CPKP infection, focusing on the risk factors for carbapenem resistance and patient mortality. The hospital department with the highest incidence of CPKP infections was the intensive care unit. All CPKP strains examined were positive for bla

Identifiants

pubmed: 30810470
doi: 10.1089/mdr.2018.0339
pmc: PMC6441289
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

287-296

Références

J Exp Med. 2004 Mar 1;199(5):697-705
pubmed: 14993253
J Clin Microbiol. 2005 Aug;43(8):4178-82
pubmed: 16081970
Clin Infect Dis. 2006 May 15;42(10):1351-8
pubmed: 16619144
Clin Infect Dis. 2007 Aug 1;45(3):284-93
pubmed: 17599305
Diagn Microbiol Infect Dis. 2008 Sep;62(1):1-6
pubmed: 18486404
FEMS Microbiol Lett. 2008 Jul;284(2):247-52
pubmed: 18507682
Shock. 2009 Feb;31(2):146-50
pubmed: 18636041
Int J Antimicrob Agents. 2009 Aug;34(2):111-20
pubmed: 19403273
J Med Microbiol. 2010 May;59(Pt 5):541-7
pubmed: 20110386
Diagn Microbiol Infect Dis. 2011 May;70(1):119-23
pubmed: 21398074
Clin Infect Dis. 2011 Jul 1;53(1):60-7
pubmed: 21653305
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13
pubmed: 22252816
Infection. 2013 Apr;41(2):503-9
pubmed: 23271210
Virulence. 2013 Feb 15;4(2):107-18
pubmed: 23302790
Expert Rev Anti Infect Ther. 2013 Feb;11(2):159-77
pubmed: 23409822
Lancet Infect Dis. 2013 Sep;13(9):785-96
pubmed: 23969216
Antimicrob Agents Chemother. 2014 Sep;58(9):5379-85
pubmed: 24982067
Curr Opin Infect Dis. 2014 Dec;27(6):479-83
pubmed: 25259809
J Clin Microbiol. 2014 Dec;52(12):4377-80
pubmed: 25275000
Clin Infect Dis. 2015 May 1;60(9):1319-25
pubmed: 25586681
J Antimicrob Chemother. 2015 Jul;70(7):2133-43
pubmed: 25900159
Sci Rep. 2015 Jul 21;5:12275
pubmed: 26194736
Am J Epidemiol. 2016 Mar 1;183(5):471-9
pubmed: 26861238
Clin Microbiol Infect. 2016 Mar;22 Suppl 1:S9-14
pubmed: 27000156
MBio. 2016 Jun 28;7(3):
pubmed: 27353756
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6115-20
pubmed: 27480857
Am J Infect Control. 2017 Jan 1;45(1):77-79
pubmed: 27597392
Eur J Clin Microbiol Infect Dis. 2017 Apr;36(4):663-669
pubmed: 27909821
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1125-1131
pubmed: 28102514
J Hosp Infect. 2017 Jun;96(2):111-115
pubmed: 28389093
Int J Antimicrob Agents. 2017 Aug;50(2):237-241
pubmed: 28648647
Microb Drug Resist. 2018 Mar;24(2):190-198
pubmed: 28749714
Lancet Infect Dis. 2018 Jan;18(1):37-46
pubmed: 28864030
Arch Med Res. 2017 Nov;48(8):727-734
pubmed: 29221800
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Clin Microbiol Rev. 1998 Oct;11(4):589-603
pubmed: 9767057

Auteurs

Hongying Pan (H)

1 Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.

Yaling Lou (Y)

2 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
3 Department of Infectious Diseases, Dongyang People's Hospital, Jinhua, China.

Linyan Zeng (L)

4 Department of Intensive Care Unit, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Li Wang (L)

2 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Jiajie Zhang (J)

1 Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.

Wei Yu (W)

1 Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
2 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Yunqing Qiu (Y)

2 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH